Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Blood - 13 Aug 2015

Gunasekera Devi, Ettinger Ruth A, Nakaya Fletcher Shelley, James Eddie A, Liu Maochang, Barrett John C, Withycombe Janice, Matthews Dana C, Epstein Melinda S, Hughes Richard J, Pratt Kathleen P

Abstract excerpt

African American hemophilia A (HA) patients experience a higher incidence of neutralizing anti-factor VIII (FVIII) antibodies ("inhibitors") vis-à-vis white patients. Nonsynonymous single-nucleotide polymorphisms (ns-SNPs) in the F8 gene encoding FVIII-H484, FVIII-E1241, and FVIII-V2238 are more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Autoantibodies
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitope Mapping

Share to Factor VIII

Share to Hemophilia A

Share to HLA-DRB1 Chains

Share to Mutant Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25617427
DOI: 10.1182/blood-2014-09-599365
PMCID: PMC4536543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25617427-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.PMID 25617427Read ↗

Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.Semantic proximity Read ↗

Race, ethnicity, F8 variants, and inhibitor risk: analysis of the "My Life Our Future" hemophilia A database.Semantic proximity Read ↗

HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdatasetSemantic proximity Read ↗

<i>In silico</i> calculated affinity of FVIII‐derived peptides for <scp>HLA</scp> class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 geneSemantic proximity Read ↗

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.Semantic proximity Read ↗

Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment.Semantic proximity Read ↗

Correlation between factor VIII genotype and inhibitor development in hemophilia A.Semantic proximity Read ↗

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.Semantic proximity Read ↗

Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients.Semantic proximity Read ↗

F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.Semantic proximity Read ↗

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.Semantic proximity Read ↗

FVIII Immunogenicity-Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.